Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bergisch Gladbach – page 94

1 418 clinical trials in Bergisch Gladbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bergisch Gladbach at a glance
1 418
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 418 trials in Bergisch Gladbach

Open in trial search

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Study of Emrusolmin for Treating Adults with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emrusolmin
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Neoplasm

Not recruiting

Study for Patients with Advanced Cancer Continuing Ribociclib Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nazartinib
  • Sponsor:Novartis Pharma AG

Neuroblastoma+4

Not recruiting

Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Ribociclib
  • Sponsor:Novartis Pharma AG

Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Arteriosclerosis+1

Not recruiting

Study on Reducing Lipoprotein Apheresis with Pelacarsen in Patients with High Lipoprotein(a) and Heart Disease in Germany

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study of nivolumab, relatlimab and bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bergisch Gladbach

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, exploring new therapeutic combinations to improve patient outcomes.

  • Early-stage breast cancer therapies
  • Advanced breast cancer treatments
  • Endocrine therapy combinations

Studies evaluating breakthrough medications like ribociclib, elacestrant, and abemaciclib in combination with standard treatments.

02 Prostate Cancer Studies

Comprehensive research targeting metastatic prostate cancer, including both castration-resistant and castration-sensitive forms of the disease.

  • Advanced hormone therapy approaches
  • Novel treatment combinations
  • Biochemical recurrence management

Trials examining innovative treatments including darolutamide and new therapeutic protocols for different stages of disease progression.

03 Supportive Care Research

Studies addressing treatment-related side effects, particularly focusing on vasomotor symptoms in cancer patients undergoing hormone therapy.

  • Quality of life improvements
  • Side effect management
  • Treatment optimization

Investigation of new compounds like elinzanetant for managing therapy-induced symptoms in cancer patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.